Alliancebernstein L.P. Has $271,000 Position in Dynavax Technologies Corporation (DVAX)

Alliancebernstein L.P. maintained its stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,620 shares of the biopharmaceutical company’s stock at the end of the first quarter. Alliancebernstein L.P. owned about 0.10% of Dynavax Technologies Corporation worth $271,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of DVAX. DekaBank Deutsche Girozentrale bought a new stake in shares of Dynavax Technologies Corporation during the first quarter valued at approximately $121,000. American International Group Inc. boosted its stake in shares of Dynavax Technologies Corporation by 7.1% in the first quarter. American International Group Inc. now owns 23,934 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 1,584 shares during the period. Parametric Portfolio Associates LLC boosted its stake in shares of Dynavax Technologies Corporation by 3.6% in the first quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 939 shares during the period. Nationwide Fund Advisors boosted its stake in shares of Dynavax Technologies Corporation by 11.2% in the first quarter. Nationwide Fund Advisors now owns 27,667 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 2,786 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in shares of Dynavax Technologies Corporation by 30.0% in the first quarter. Wells Fargo & Company MN now owns 41,743 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 9,634 shares during the period. 57.49% of the stock is owned by institutional investors.

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) traded up 0.62% during mid-day trading on Wednesday, reaching $16.30. 102,355 shares of the company traded hands. Dynavax Technologies Corporation has a 52-week low of $3.20 and a 52-week high of $19.60. The company’s 50 day moving average is $12.06 and its 200 day moving average is $7.35. The stock’s market capitalization is $892.38 million.

Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.09. The business had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.15 million. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. During the same period last year, the business posted ($0.75) EPS. On average, equities analysts forecast that Dynavax Technologies Corporation will post ($1.58) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://sportsperspectives.com/2017/08/16/alliancebernstein-l-p-has-271000-position-in-dynavax-technologies-corporation-dvax.html.

DVAX has been the topic of several recent research reports. Zacks Investment Research raised shares of Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Monday, July 10th. Royal Bank Of Canada set a $7.00 target price on shares of Dynavax Technologies Corporation and gave the stock a “hold” rating in a research note on Wednesday, July 26th. BidaskClub cut shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Cowen and Company reaffirmed an “outperform” rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a research note on Thursday, August 10th. Finally, William Blair reissued an “outperform” rating and set a $30.00 price target on shares of Dynavax Technologies Corporation in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $23.34.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Corporation (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply